文献速递冠心病血脂与心血管预防

急性心肌梗死后多种预防治疗依从性权衡与全因死亡率

Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

研究纳入90,869例≥65岁 Medicare 受益者,分析急性心肌梗死后对 ACEI/ARB、β受体阻滞剂和他汀的依从性权衡与生存的关系。仅49%患者对三种治疗均依从(PDC≥80%)。与全部三种依从相比,仅 ACEI/ARB 加他汀依从者死亡率相似(HR 0.98,95%CI 0.91-1.07),而其他部分依从及完全不依从者死亡率升高。

要点

  • 仅49%心梗后老年患者对 ACEI/ARB、β受体阻滞剂和他汀三种治疗均依从。
  • 仅 ACEI/ARB 加他汀依从者死亡率与全部三种依从者相似。
  • 对 ACEI/ARB 和/或他汀不依从与死亡率升高相关。

核心结论

  • 仅 ACEI/ARB 加他汀依从者死亡率与全部三种治疗依从者相似,提示在他汀和 ACEI/ARB 依从患者中 β受体阻滞剂额外获益有限。
  • 对 ACEI/ARB 和/或他汀不依从与死亡率升高相关。

研究设计与样本

  • 回顾性队列研究,纳入90,869例≥65岁 Medicare 受益者,2008至2010年急性心肌梗死住院后存活≥180天且有权衡三种药物处方。
  • 依从性以出院后180天内覆盖天数比例(PDC)衡量,死亡率随访至该期间后18个月。
  • 采用 Cox 比例风险模型估计部分依从组相对于全部三种依从组的死亡风险比。

主要发现

  • 仅49%患者对全部三种治疗依从(PDC≥80%)。
  • 与全部三种依从相比,仅 ACEI/ARB 加 β受体阻滞剂依从者死亡 HR 为1.12(95%CI 1.04-1.21)。
  • 仅 ACEI/ARB 加他汀依从者死亡 HR 为0.98(95%CI 0.91-1.07)。
  • 仅 β受体阻滞剂加他汀依从者死亡 HR 为1.17(95%CI 1.10-1.25);仅 ACEI/ARB 依从者 HR 1.19(95%CI 1.07-1.32)。
  • 仅 β受体阻滞剂依从者 HR 1.32(95%CI 1.21-1.44);仅他汀依从者 HR 1.26(95%CI 1.15-1.38);三种均不依从者 HR 1.65(95%CI 1.54-1.76)。

临床怎么用

  • 心梗后老年患者应优先保障 ACEI/ARB 和他汀的依从性,对 β受体阻滞剂耐受不佳者可考虑其额外获益有限。
  • 评估依从性时需关注 ACEI/ARB 和他汀的持续使用,不依从与死亡风险升高相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARB), beta-blockers and statins are recommended after acute myocardial infarction (AMI). Patients may adhere to some, but not all, therapies. OBJECTIVES: The authors investigated the effect of tradeoffs in adherence to ACE inhibitors/ARBs, beta-blockers, and statins on survival among older people after AMI. METHODS: The authors identified 90,869 Medicare beneficiaries ≥65 years of age who had prescriptions for ACE inhibitors/ARBs, beta-blockers, and statins, and survived ≥180 days after AMI hospitalization in 2008 to 2010. Adherence was measured by proportion of days covered (PDC) during 180 days following hospital discharge. Mortality follow-up extended up to 18 months after this period. The authors used Cox proportional hazards models to estimate hazard ratios of mortality for groups adherent to 2, 1, or none of the therapies versus group adherent to all 3 therapies. RESULTS: Only 49% of the patients adhered (PDC ≥80%) to all 3 therapies. Compared with being adherent to all 3 therapies, multivariable-adjusted hazard ratios (95% confidence intervals [CIs]) for mortality were 1.12 (95% CI: 1.04 to 1.21) for being adherent to ACE inhibitors/ARBs and beta-blockers only, 0.98 (95% CI: 0.91 to 1.07) for ACEI/ARBs and statins only, 1.17 (95% CI: 1.10 to 1.25) beta-blockers and statins only, 1.19 (95% CI: 1.07 to 1.32) for ACE inhibitors/ARBs only, 1.32 (95% CI: 1.21 to 1.44) for beta-blockers only, 1.26 (95% CI: 1.15 to 1.38) statins only, and 1.65 (95% CI: 1.54 to 1.76) for being nonadherent (PDC <80%) to all 3 therapies. CONCLUSIONS: Patients adherent to ACE inhibitors/ARBs and statins only had similar mortality rates as those adherent to all 3 therapies, suggesting limited additional benefit for beta-blockers in patients who were adherent to statins and ACE inhibitors/ARBs. Nonadherence to ACE inhibitors/ARBs and/or statins was associated with higher mortality.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Korhonen MJ, Robinson JG, Annis IE, et al. Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction. J Am Coll Cardiol. 2017. PMID: 28935030. doi:10.1016/j.jacc.2017.07.783

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。